Comparing the effects of bevacizumab and aflibercept in the treatment and outcome of patients with retinopathy of prematurity (ROP)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240611062093N1

Enrollment

Registered

2024-08-08

Start date

2024-08-20

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention 1: Bevacizumab is an anti-angiogenic drug with a protein structure with a molecular weight of 149 kilodaltons manufactured by Ariogen Pharmed Company with a concentration of 4.100 ml in e

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Completion of patient files Patients who need treatment Patients needing treatment with anti-VEGF drugs

Exclusion criteria

Exclusion criteria: Patients with underlying disease, including congenital glaucoma, congenital cataract Patients with vitreous hemorrhages

Design outcomes

Primary

Measure	Time frame
Improve pupil function. Timepoint: 2 weeks, 1 month and 3 months after the intervention. Method of measurement: Pupil dilation.;Improve retinal function. Timepoint: 2 weeks, 1 month and 3 months after the intervention. Method of measurement: Complete retinal examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIbrahim Ruhol Amini

Zahedan University of Medical Sciences

ebrahimrohoolamini@gmail.com+98 54 3337 2151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026